Media ReleasesChimeric Therapeutics

View All Chimeric Therapeutics News

First milestone on path to CDH17 CAR T clinical trial

• Phase 1 plasmid manufacturing commenced
• Phase 1 clinical trial for neuroendocrine & colorectal tumors planned for 2022
• Positions Chimeric to have a minimum of two Phase 1 trials underway during 2022

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and the ASX leader in cell therapy, is pleased to announce the successful completion of manufacturing for CHM 2101 research grade plasmids, a critical first step in the development of CDH17 CAR T.

Manufacturing of CAR T therapies is dependent upon plasmids and viral vectors that hold the genetic instructions for each specific CAR T product. Plasmids are small DNA molecules that carry genetic instructions and their successful manufacture marks an important  early step for all CAR T therapies.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.